[Form 4] Cytokinetics Inc. Insider Trading Activity
Insider transactions by Dr. Malik Fady Ibraham, EVP Research & Development of Cytokinetics (CYTK), are reported on Form 4. On 08/19/2025 he exercised 2,000 non鈥憅ualified stock options at an exercise price of $10.60 and concurrently sold 2,000 shares at $38.31. After these transactions he beneficially owned 140,610 shares. The filing shows 9,105 option shares remaining exercisable from the option series.
Le operazioni insider effettuate dal Dr. Malik Fady Ibraham, EVP Ricerca e Sviluppo di Cytokinetics (CYTK), sono riportate nel Modulo 4. In data 19/08/2025 ha esercitato 2.000 opzioni su azioni non qualificate al prezzo di esercizio di $10.60 e contemporaneamente ha venduto 2.000 azioni a $38.31. Dopo queste operazioni deteneva beneficiariamente 140.610 azioni. Il deposito indica che rimangono esercitabili 9.105 azioni opzione appartenenti alla serie di opzioni.
Las transacciones de insider del Dr. Malik Fady Ibraham, EVP de Investigaci贸n y Desarrollo de Cytokinetics (CYTK), se informan en el Formulario 4. El 19/08/2025 ejerci贸 2.000 opciones sobre acciones no calificadas a un precio de ejercicio de $10.60 y, de forma simult谩nea, vendi贸 2.000 acciones a $38.31. Tras estas operaciones pose铆a beneficiariamente 140.610 acciones. La presentaci贸n muestra que quedan ejercitables 9.105 acciones de opci贸n de la serie.
Cytokinetics(CYTK)鞚� 鞐瓣惮臧滊皽 雼措嫻 EVP鞚� Malik Fady Ibraham 氚曥偓鞚� 雮措秬鞛� 瓯半灅電� 鞏戩嫕 4鞐� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 2025雲� 8鞗� 19鞚� 攴鸽姅 頄夓偓臧�瓴� $10.60鞚� 牍勳瀽瓴� 鞀ろ啞鞓奠厴 2,000欤茧ゼ 頄夓偓頃橁碃 霃欖嫓鞐� 2,000欤茧ゼ 欤茧嫻 $38.31鞐� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 攴胳潣 鞁れ 氤挫湢 欤检嫕鞚� 140,610欤检榾鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 頃措嫻 鞓奠厴 鞁滊Μ歃堨棎靹� 頄ロ泟 頄夓偓 臧�電ロ暅 鞓奠厴 欤检嫕鞚� 9,105欤� 雮晞 鞛堧姅 瓴冹溂搿� 雮橅儉雮� 鞛堨姷雼堧嫟.
Les transactions d'initi茅 du Dr Malik Fady Ibraham, EVP Recherche & D茅veloppement de Cytokinetics (CYTK), sont d茅clar茅es sur le formulaire 4. Le 19/08/2025, il a lev茅 2 000 options d'achat d'actions non qualifi茅es au prix d'exercice de $10.60 et a simultan茅ment vendu 2 000 actions 脿 $38.31. Apr猫s ces op茅rations, il d茅tenait b茅n茅ficiairement 140 610 actions. Le d茅p么t indique qu'il reste 9 105 actions d'option exer莽ables appartenant 脿 la s茅rie d'options.
Insider-Transaktionen von Dr. Malik Fady Ibraham, EVP Forschung & Entwicklung bei Cytokinetics (CYTK), sind in Formular 4 gemeldet. Am 19.08.2025 眉bte er 2.000 nichtqualifizierte Aktienoptionen zum Aus眉bungspreis von $10.60 aus und verkaufte gleichzeitig 2.000 Aktien zu $38.31. Nach diesen Transaktionen besa脽 er wirtschaftlich 140.610 Aktien. Die Einreichung zeigt, dass aus der Optionsserie noch 9.105 aus眉bungsf盲hige Optionsaktien verbleiben.
- Exercise executed at $10.60, indicating option strike was significantly below sale price
- Reporting timely and signed by attorney-in-fact, reflecting compliance with Section 16 disclosure
- Sale of 2,000 shares reduced direct holdings from 142,610 to 140,610
- No disclosure of a 10b5-1 plan specifics beyond the checked box, so plan details are not provided
Insights
TL;DR: Officer exercised options cheaply and sold shares same day, realizing a cash difference but leaving substantial ownership.
The transaction shows a typical option exercise-and-sell-throughs (likely to cover tax or diversify) where 2,000 options were exercised at $10.60 and the resulting shares were sold at $38.31 on the same date, realizing the spread. Post-transaction beneficial ownership remains material at 140,610 shares, and 9,105 option shares remain exercisable. The activity is a routine liquidity event by an insider rather than a corporate governance change.
TL;DR: Insider sale occurred but reporting complies with Section 16 disclosure; no governance red flags in filing.
The Form 4 is complete for the reported transactions and is signed by an attorney-in-fact, indicating proper execution. The filing notes the reporter is an officer (EVP R&D). The immediate exercise and sale pattern aligns with standard insider practices; there is no indication of undisclosed related-party transactions or departures. Material governance impact appears neutral.
Le operazioni insider effettuate dal Dr. Malik Fady Ibraham, EVP Ricerca e Sviluppo di Cytokinetics (CYTK), sono riportate nel Modulo 4. In data 19/08/2025 ha esercitato 2.000 opzioni su azioni non qualificate al prezzo di esercizio di $10.60 e contemporaneamente ha venduto 2.000 azioni a $38.31. Dopo queste operazioni deteneva beneficiariamente 140.610 azioni. Il deposito indica che rimangono esercitabili 9.105 azioni opzione appartenenti alla serie di opzioni.
Las transacciones de insider del Dr. Malik Fady Ibraham, EVP de Investigaci贸n y Desarrollo de Cytokinetics (CYTK), se informan en el Formulario 4. El 19/08/2025 ejerci贸 2.000 opciones sobre acciones no calificadas a un precio de ejercicio de $10.60 y, de forma simult谩nea, vendi贸 2.000 acciones a $38.31. Tras estas operaciones pose铆a beneficiariamente 140.610 acciones. La presentaci贸n muestra que quedan ejercitables 9.105 acciones de opci贸n de la serie.
Cytokinetics(CYTK)鞚� 鞐瓣惮臧滊皽 雼措嫻 EVP鞚� Malik Fady Ibraham 氚曥偓鞚� 雮措秬鞛� 瓯半灅電� 鞏戩嫕 4鞐� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 2025雲� 8鞗� 19鞚� 攴鸽姅 頄夓偓臧�瓴� $10.60鞚� 牍勳瀽瓴� 鞀ろ啞鞓奠厴 2,000欤茧ゼ 頄夓偓頃橁碃 霃欖嫓鞐� 2,000欤茧ゼ 欤茧嫻 $38.31鞐� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 攴胳潣 鞁れ 氤挫湢 欤检嫕鞚� 140,610欤检榾鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 頃措嫻 鞓奠厴 鞁滊Μ歃堨棎靹� 頄ロ泟 頄夓偓 臧�電ロ暅 鞓奠厴 欤检嫕鞚� 9,105欤� 雮晞 鞛堧姅 瓴冹溂搿� 雮橅儉雮� 鞛堨姷雼堧嫟.
Les transactions d'initi茅 du Dr Malik Fady Ibraham, EVP Recherche & D茅veloppement de Cytokinetics (CYTK), sont d茅clar茅es sur le formulaire 4. Le 19/08/2025, il a lev茅 2 000 options d'achat d'actions non qualifi茅es au prix d'exercice de $10.60 et a simultan茅ment vendu 2 000 actions 脿 $38.31. Apr猫s ces op茅rations, il d茅tenait b茅n茅ficiairement 140 610 actions. Le d茅p么t indique qu'il reste 9 105 actions d'option exer莽ables appartenant 脿 la s茅rie d'options.
Insider-Transaktionen von Dr. Malik Fady Ibraham, EVP Forschung & Entwicklung bei Cytokinetics (CYTK), sind in Formular 4 gemeldet. Am 19.08.2025 眉bte er 2.000 nichtqualifizierte Aktienoptionen zum Aus眉bungspreis von $10.60 aus und verkaufte gleichzeitig 2.000 Aktien zu $38.31. Nach diesen Transaktionen besa脽 er wirtschaftlich 140.610 Aktien. Die Einreichung zeigt, dass aus der Optionsserie noch 9.105 aus眉bungsf盲hige Optionsaktien verbleiben.
FAQ
What transactions did CYTK insider Malik Fady Ibraham report on Form 4?
How many CYTK shares does the reporting person own after the transactions?
Are there remaining exercisable options reported for the insider?
Did the filing indicate the transaction was made under a 10b5-1 plan?
What is the reporting person's role at Cytokinetics?
